SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-24-010920
Filing Date
2024-03-04
Accepted
2024-03-04 07:00:28
Documents
14
Period of Report
2024-03-01
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K ef20022786_8k.htm   iXBRL 8-K 31374
  Complete submission text file 0001140361-24-010920.txt   167978

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA bbio-20240301.xsd EX-101.SCH 3868
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20240301_lab.xml EX-101.LAB 21966
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20240301_pre.xml EX-101.PRE 16046
15 EXTRACTED XBRL INSTANCE DOCUMENT ef20022786_8k_htm.xml XML 4225
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 24712813
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)